Literature DB >> 8439480

Glomerular injury in end-stage liver disease--role of circulating IgG and IgM immune complexes.

L S Milner1, M T Houser, P C Kolbeck, D L Antonson, T L McDonald, R S Markin, B W Shaw.   

Abstract

The relationship of IgG- and IgM-bound circulating immune complexes and immune dysfunction to glomerular injury was evaluated in 15 children with end-stage liver disease (ESLD) awaiting liver transplantation. Compared with age-matched controls, children with ESLD had significantly (P < 0.01) increased serum IgG, IgA, and IgM levels, as well as IgG- and IgM-bound circulating immune complexes. Furthermore, they showed a significant (P < 0.05) depression of C3 and C4 levels compared with controls. Hematuria occurred in 66% of children with ESLD, and the urinary protein/creatinine ratio was also significantly (P < 0.01) increased compared with controls (4.65 +/- 2.56 vs. 0.16 +/- 0.04 mg/mg). Light microscopy of renal biopsy tissue obtained from 6 children with ESLD at the time of transplantation demonstrated mesangial proliferation and expansion with basement membrane splitting. This was associated with subendothelial deposits on electron-microscopic examination, compatible with a diagnosis of membranoproliferative glomerulonephritis. By immunofluorescence, deposition of IgG, IgA, and IgM occurred in various combinations with co-deposition of complement fragments. We conclude that membranoproliferative glomerulonephritis is a common finding in children with ESLD, probably due to entrapment of circulating IgG- and IgM-bound immune complexes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439480     DOI: 10.1007/bf00861550

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  37 in total

1.  Charge distribution of plasma IgA in IgA nephropathy.

Authors:  T Harada; P Hobby; M Courteau; J F Knight; D G Williams
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

2.  Serum immunoglobulins, complement component levels and autoantibodies in liver disease.

Authors:  R A Thompson; R Carter; R P Stokes; A M Geddes; J A Goodall
Journal:  Clin Exp Immunol       Date:  1973-07       Impact factor: 4.330

3.  Immunoglobulins in chronic liver disease.

Authors:  T Feizi
Journal:  Gut       Date:  1968-04       Impact factor: 23.059

4.  Renal lesions associated with cirrhosis of the liver in infancy and childhood.

Authors:  R T O'Kell
Journal:  Am J Dis Child       Date:  1968-07

Review 5.  IgA nephropathy in chronic liver disease.

Authors:  D Nochy; P Druet; J Bariety
Journal:  Contrib Nephrol       Date:  1984       Impact factor: 1.580

6.  Quantitative determination of complement components produced by purified hepatocytes.

Authors:  G Ramadori; H Rasokat; R Burger; K H Meyer Zum Büschenfelde; D Bitter-Suermann
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

7.  Immunoglobulin isotypes in the circulating immune complexes of diabetic rats with and without proteinuria: a chronological study.

Authors:  G M Thiele; T L McDonald
Journal:  J Clin Lab Immunol       Date:  1987-01

8.  Experimental IgA nephropathy in bile duct ligated rats.

Authors:  T Melvin; B Burke; A F Michael; Y Kim
Journal:  Clin Immunol Immunopathol       Date:  1983-06

9.  IgA-associated glomerular deposits in liver disease.

Authors:  C Abramowsky; B Dahms; G Swinehart
Journal:  Hum Pathol       Date:  1985-12       Impact factor: 3.466

10.  Hyperglobulinaemia in chronic liver disease: relationships between in vitro immunoglobulin synthesis, short lived suppressor cell activity and serum immunoglobulin levels.

Authors:  P B Rong; J Kalsi; H J Hodgson
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

View more
  1 in total

1.  Hepatic-associated immunoglobulin-A nephropathy in a child with liver cirrhosis and portal hypertension.

Authors:  Sharifa A Alghamdi; Omar I Saadah; Nesreen Almatury; Jaudah Al-Maghrabi
Journal:  Saudi J Gastroenterol       Date:  2012 May-Jun       Impact factor: 2.485

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.